Corvus Pharmaceuticals CRVS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -30.5%+2.1pp | -32.6%+3.2pp | -35.8%+32.9pp | -68.7%+31.5pp | -100.1%+74.7pp | |
| Return on invested capital | -38.8%+65.3pp | -104.2%-4.5pp | -99.6%-31.1pp | -68.5%+17.7pp | -86.2%+19.0pp | |
| Liquidity | ||||||
| Current ratio | 19.8×+13.6× | 6.2×-2.1× | 8.3×-0.6× | 8.9×+4.0× | 4.9×+3.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.67+248% | $0.77-11.4% | $0.87-16.0% | $1.03+57.2% | $0.66+22.9% | |
| Valuation | ||||||
| Market capitalization | $1.1B+259% | $575.05M+4.7% | $549.17M+64.1% | $334.68M+54.5% | $216.67M-37.0% | |
| Price / book | 4.6×-1.6× | 9.4×+1.7× | 7.7×+3.5× | 4.2×-0.2× | 4.4×-6.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Corvus Pharmaceuticals's ratios come from?
- Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.